Skip to main content

Table 2 Pegvaliase exposure

From: Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

 

Phase 2 participants (N = 80)

Treatment duration, weeks

 Mean (SD)

167.0 (111.1)

 Min, max

0.71, 370.4

Treatment duration, n (%)

  < 1 year

15 (18.8%)

  ≥ 1 to < 2 years

12 (15.0%)

  ≥ 2 to < 3 years

10 (12.5%)

  ≥ 3 to < 4 years

12 (15.0%)

  ≥ 4 years

31 (38.8%)

  1. All data from phase 2 studies are included
  2. max maximum, min minimum, SD standard deviation